Please assess the completion status of the following clinical trial:

Trial Title: The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (over 18)~* Suffering from atopic eczema with symptoms of redness, dry skin, scaling and/or itchiness on hands or arms~* Otherwise healthy~* Able to provide informed consent~Exclusion Criteria:~* Active allergic skin responses~* Unstable or serious illness (eg kidney, liver, GIT, heart conditions, diabetes, mood disorders, cancer)~* Use of immunosuppressive medication within the last 3 months~* Pregnant or lactating women~* Smokers~* Chronic past and/or current alcohol use (\>14 alcoholic drinks week)~* Allergic to any of the ingredients in active or comparator formula~  * An unstable illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity. A serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1.5% Palmitoylethanolamide (PEA) sold as Levagen+ (Type: EXPERIMENTAL): Investigational product will be provided as a topical cream containing 1.5% PEA and participants will be asked to apply to their affected site 2 times daily for 4 weeks. Cream should be applied liberally (as you would a moisturiser cream) such to coat the affected area and absorb into the skin.
- Placebo comparator (Type: PLACEBO_COMPARATOR): A comparator placebo moisturiser cream (an unscented moisturizing base cream) will be provided and applied in the same manner as the active ingredient group. Participants will be asked to apply to their affected site 2 times daily for 4 weeks. Cream should be applied liberally (as you would a moisturiser cream) such to coat the affected area and absorb into the skin.

Based on this trial design, predict the completion outcome and termination type (if applicable).